Long-term effects of iron deficiency in patients with heart failure with or without anemia: the RAID-HF follow-up study

Clinical Research in Cardiology

Volumn 108, Issue 1, 2019, Pages 93-100

  Wienbergen, Harm ^a   Pfister, Otmar ^b   Hochadel, Matthias ^c   Fach, Andreas ^a   Backhaus, Tina ^a   Bruder, Oliver ^d   Remppis, Björn Andrew ^e   Maeder, Micha Tobias ^f   von Scheidt, Wolfgang ^g   Pauschinger, Matthias ^h   Senges, Jochen ^c   Hambrecht, Rainer ^a  

^a Institut für Herz und Kreislaufforschung am Klinikum Links der Weser Bremen BIHKF   (Germany)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

^c Stiftung Institut für Herzinfarktforschung IHF   (Germany)

^d ELISABETH KRANKENHAUS ESSEN   (Germany)

^e Division of Cardiology   (Germany)

^f CANTONAL HOSPITAL ST GALLEN   (Switzerland)

^g KLINIKUM AUGSBURG   (Germany)

^h KLINIKUM NÜRNBERG   (Germany)

Author keywords

Anemia; Heart failure with reduced ejection fraction; Iron deficiency; Iron supplementation

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FERRITIN; HEMOGLOBIN; IRON; MINERALOCORTICOID ANTAGONIST; TRANSFERRIN;

AGED; ANEMIA; ARTICLE; ATRIAL FIBRILLATION; CHRONIC KIDNEY FAILURE; CHRONIC OBSTRUCTIVE LUNG DISEASE; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HEART FAILURE; HEART FAILURE WITH REDUCED EJECTION FRACTION; HEMODIALYSIS; HUMAN; IRON DEFICIENCY; ISCHEMIC CARDIOMYOPATHY; MAJOR CLINICAL STUDY; MORTALITY; MORTALITY RISK; NEW YORK HEART ASSOCIATION CLASS; OBSERVATIONAL STUDY; PROGNOSIS; QUALITY OF LIFE; QUESTIONNAIRE; RISK FACTOR; CLINICAL TRIAL; COMORBIDITY; DIETARY SUPPLEMENT; GERMANY; HEART STROKE VOLUME; IRON DEFICIENCY ANEMIA; MALE; MULTICENTER STUDY; PATHOPHYSIOLOGY; PHYSIOLOGY; PROCEDURES; REGISTER; RISK ASSESSMENT; SURVIVAL RATE; SWITZERLAND; TIME FACTOR; TRENDS;

AGED; ANEMIA, IRON-DEFICIENCY; COMORBIDITY; DIETARY SUPPLEMENTS; FEMALE; FOLLOW-UP STUDIES; GERMANY; HEART FAILURE; HUMANS; IRON; MALE; PROGNOSIS; QUALITY OF LIFE; REGISTRIES; RISK ASSESSMENT; STROKE VOLUME; SURVIVAL RATE; SWITZERLAND; TIME FACTORS;

EID: 85049778808     PISSN: 18610684     EISSN: 18610692     Source Type: Journal    
DOI: 10.1007/s00392-018-1327-y     Document Type: Article

References (32)

1. Jankowska EA, Rozentryt P, Witkowska A, Nowak J, Hartmann O, Ponikowska B et al (2010) Iron deficiency: an ominous sign in patients with systolic chronic heart failure. Eur Heart J 31:1872–1880
2. Klip IT, Comin-Colet J, Voors AA, Ponikowski P, Enjuanes C, Banasiak W et al (2013) Iron deficiency in chronic heart failure: an international pooled analysis. Am Heart J 165(4):575–582
3. Jankowska EA, rozentryt P, Witkowska A, Nowak J, Hartmann O, Ponikowska B et al (2011) Iron deficiency predicts impaired exercise capacity in patients with systolic chronic heart failure. J Card Fail 17:899–906
4. Enjuanes C, Klip IT, Brugera J, Cladellas M, Ponikowski P, Banasiak W et al (2014) Iron deficiency and health-related quality of life in chronic heart failure: results from a multicenter European study. Int J Cardiol 174:268–275
5. Okonko DO, Grzeslo A, Witkowski T, Mandai AK, Slater RM, Roughton M et al (2008) Effect of intravenous iron sucrose on exercise tolerance in anemic and nonanemic patients with symptomatic chronic heart failure and iron deficiency FERRIC-HF: a randomized, controlled, observer-blinded trial. J Am Coll Cardiol 51:103–112
6. Anker SD, Comin-Colet J, Filippatos G, Willenheimer R, Dickstein K, Drexler H et al (2009) Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med 361:2436–2448
7. Ponikowski P, van Veldhuisen DJ, Comin-Colet J, Ertl G, Komajda M, Mareev V et al (2015) Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency. Eur Heart J 36:657–668
8. Beck-da-Silva L, Piardi D, Soder S, Rohde LE, Pereira-Barretto AC, de Albuquerque D et al (2013) IRON-HF study: a randomized trial to assess the effects of iron in heart failure patients with anemia. Int J Cardiol 168:3439–3442
9. Anker SD, Kirwan BA, van Veldhuisen DJ, Filippatos G, Comin-Colet J, Ruschitzka F et al (2018) Effects of ferric carboxymaltose on hospitalisations and mortality rates in iron-deficient heart failure patients: an individual patient data meta-analysis. Eur J Heart Fail 20:125–133
10. Hasenfuß G, Anker S, Bauersachs J, Böhm M, Hoppe UC, Pieske B et al (2013) Kommentar zu den Leitlinien der Europäischen Gesellschaft für Kardiologie (ESC) zur Diagnostik und Behandlung der akuten und chronischen Herzinsuffizienz. Kardiologe 7:105–114
11. McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Böhm M, Dickstein K et al (2012) ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the task force for the diagnosis and treatment of acute and chronic heart failure 2012 of the European Society of Cardiology. Eur Heart J 33:1787–1847
12. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ et al (2016) 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Eur Heart J 37:2129–2200
13. Wienbergen H, Pfister O, Hochadel M, Michel S, Bruder O, Remppis BA et al (2016) Usefulness of iron deficiency correction in management of patients with heart failure [from the registry analysis of iron deficiency-heart failure (RAID-HF) registry]. Am J Cardiol 118:1875–1880
14. World Health Organization. Worldwide prevalence of anaemia 1993–2005. WHO global database on anaemia. https://www.who.int. Accessed 16 Jun 2018
15. Levey AS, Coresh J, Balk E, Kausz AT, Levin A, Steffes MW et al (2003) National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med 139:137–147
16. EuroQoL group (2017) EQ-5D instruments. https://www.euroqol.org/eq-5d-instruments/. Accessed 16 Jun 2018
17. Kaspar M, Fette G, Güder G, Seidlmayer L, Ertl M, Dietrich G et al (2018) Underestimated prevalence of heart failure in hospital inpatients: a comparison of ICD codes and discharge letter information. Clin Res Cardiol. 10.1007/s00392-018-1245-z (Epub ahead of print)
18. Llorens P, Javaloyes P, Martín-Sánchez FJ, Jacob J, Herrero-Puente P, Gil V et al (2018) Time trends in characteristics, clinical course, and outcomes of 13,791 patients with acute heart failure. Clin Res Cardiol. 10.1007/s00392-018-1261-z (Epub ahead of print)
19. Riedel O, Ohlmeier C, Enders D, Elsässer A, Vizcaya D, Michel A et al (2018) The contribution of comorbidities to mortality in hospitalized patients with heart failure. Clin Res Cardiol 107:487–497
20. Jankowska EA, Kasztura M, Sokolski M, Bronisz M, Nawrocka S, Oleskowska-Florek W et al (2014) Iron deficiency defined as depleted iron stores accompanied by unmet cellular iron requirements identifies patients at the highest risk of death after an episode of acute heart failure. Eur Heart J 35:2468–2476
21. Haddad S, Wang Y, Galy B, Korf-Klingebeil M, Hirsch V, Baru AM et al (2017) Iron-regulatory proteins secure iron availability in cardiomyocytes to prevent heart failure. Eur Heart J 38:362–372
22. von Haehling S, Gremmler U, Krumm M, Mibach F, Schon N, Taggeselle J et al (2017) Prevalence and clinical impact of iron deficiency and anaemia among outpatients with chronic heart failure: The PrEP Registry. Clin Res Cardiol 106:436–443
23. Okonko DO, Mandal AK, Missouris CG, Poole-Wilson PA (2011) Disordered iron homeostasis in chronic heart failure: prevalence, predictors, and relation to anemia, exercise capacity, and survival. J Am Coll Cardiol 58:1241–1251
24. van Veldhuisen DJ, Ponikowski P, van der Meer P, Metra M, Böhm M, Doletsky A et al (2017) Effect of ferric carboxymaltose on exercise capacity in patients with chronic heart failure and iron deficiency. Circulation 136:1374–1383
25. Keating GM (2015) Ferric carboxymaltose: a review of its use in iron deficiency. Drugs 75:101–127
26. Gutzwiller FS, Schwenkglenks M, Blank PR, Braunhofer PG, Mori C, Szucs TD et al (2012) Health economic assessment of ferric carboxymaltose in patients with iron deficiency and chronic heart failure based on the FAIR-HF trial: an analysis for the UK. Eur J Heart Fail 14:782–790
27. Lewis GD, Malhotra R, Hernandez AF, McNulty SE, Smith A, Felker GM et al (2017) Effect of oral iron repletion on exercise capacity in patients with heart failure with reduced ejection fraction and iron deficiency: the IRONOUT HF randomized clinical trial. JAMA 317:1958–1966
28. Tkaczyszyn M, Comin-Colet J, Voors AA, van Veldhuisen DJ, Enjuanes C, Moliner-Borja P et al (2018) Iron deficiency and red cell indices in patients with heart failure. Eur J Heart Fail 20:114–122
29. Ebner N, Jankowska EA, Ponikowski P, Lainscak M, Elsner S, Sliziuk V et al (2016) The impact of iron deficiency and anaemia on exercise capacity and outcomes in patients with chronic heart failure. Results from the studies investigating co-morbidities aggravating heart failure. Int J Cardiol 205:6–12
30. Grote Beverborg N, van Veldhuisen DJ, van der Meer P (2018) Anemia in heart failure: still relevant? JACC Heart Fail 6:201–208
31. Parikh A, Natarajan S, Lipsitz SR, Katz SD (2011) Iron deficiency in community-dwelling US adults with self-reported heart failure in the National Health and Nutrition Examination Survey III: prevalence and associations with anemia and inflammation. Circ Heart Fail 4:599–606
32. Swedberg K, Young JB, Anand IS, Cheng S, Desai AS, Diaz R et al (2013) Treatment of anemia with darbepoetin alfa in systolic heart failure. N Engl J Med 368:1210–1219